MAPT and Alzheimer disease: Currently, Aβ and tau pathologies remain the focus of new therapies undergoing clinical trials for AD, which include monoclonal antibodies targeting Aβ[50, 88, 109, 131], the β-secretase (BACE1) inhibitor that inhibits secretase activity to lessen Aβ deposition [35], and drugs that target tau protein [94].